We evaluated the depletion of TCR-alpha/beta cells from the graft of children with high-risk AML, who received transplantation from unrelated (n = 20) and haploidentical donors (n = 13). The preparative regimen included treosulfan, melphalan, fludarabine and anti-thymocyte globulin. Grafts were PBSC engineered by TCR-alpha/beta and CD19 depletion. The graft contained a median of 9 × 10 6 /kg of CD34+ and 20 × 10 3 /kg of αβ-T cells. Post-transplant immune suppression included tacrolimus till day +30 and Mtx in 21 patients, tacrolimus in 5, Mtx in 2 and no prophylaxis in 5 patients. Sixteen patients received native or TCR-alpha/beta-depleted donor lymphocytes at a median of 47 (40-204) days. Median follow-up is 1.76 years. Primary engraftment was achieved in 33 patients (100%). Cumulative incidence of acute GvHD (aGvHD) grade 2-3 was 39 (26-60)%, half of them had skin-only aGvHD. Cumulative incidence of chronic GvHD was 30(18-50)%. Transplant-related mortality is 10(4-26)%. Event-free survival (EFS) is 60 (43-76)% and overall survival (OS) is 67(50-84)% at 2 years. In a subgroup of patients, who received transplantation in CR, EFS is 66 (48-84)% and OS − 72(53-90)% at 2 years. Our data suggest that TCR-alpha/beta and CD19 depletion is a robust method of graft manipulation, which can be used to engineer grafts for children with AML
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation is a standard therapy for children with high-risk acute myeloid leukemia, including patients with unfavorable genetic variants, those who failed to achieve remission and those with relapsed disease. 1, 2 A 2-year overall survival (OS) of 50-70% is expected with the standard approach to GvHD prevention in recipients of allogeneic grafts if transplanted in CR. [3] [4] [5] The increased use of unrelated and mismatched family (haploidentical) donors became possible due to improvements in unrelated donor registries, high-resolution HLA-typing and new methods of in vivo and ex vivo graft manipulation. 6, 7 The major obstacle to the success of both unrelated and haploidentical transplantation is leukemia relapse. GvHD remains an unresolved medical problem that causes significant morbidity and mortality. 5 The depletion of T cells from the graft is the most effective method of GvHD prophylaxis, but the benefits of low GvHD incidence were often compromised by the increased risk of relapse and severe infections associated with delayed immune reconstitution. [8] [9] [10] The selective depletion of TCR-alpha/beta and CD19-positive lymphocytes from the graft has been proposed as a new method of graft manipulation. 11, 12 The goal of this manipulation is to decrease the rate of significant GvHD, whilst potentially conserving the subpopulations of leukocytes such as NK-cells and gamma/delta T cells that are presumably active against leukemia and viral infections. Early reports on the clinical results suggest that in the setting of haploidentical transplantation, this technology is associated with low transplant-related mortality (TRM) and good overall results in patients with acute leukemia and non-malignant disease. [13] [14] [15] In 2012, a number of pilot trials was initiated at our center to evaluate the potential benefits and risks associated with the use of TCR-alpha/beta and CD19 depletion to prepare hematopoietic grafts from matched unrelated donors (MUDs) and haploidentical donors. The current report summarizes the results of implementing this approach in a cohort of children with acute myeloid leukemia.
PATIENTS AND METHODS
Thirty-three consecutive pediatric patients with acute myeloid leukemia underwent allogeneic hematopoietic stem cell transplantation at the BMT department of the Dmitriy Rogachev Federal Research Center for Pediatric Hematology, Oncology and Immunology in Moscow, Russia between January 2012 and December 2013.
Thirteen patients received haploidentical grafts, and 20 received a graft from a MUD. Matched donor was defined as 10/10 or 9/10 match by sequence-based HLA-typing. Killer immunoglobulin-like receptor (KIR) genotyping was not performed and KIR mismatch was predicted from HLA-C and B type in 5 out of 13 haploidentical donor-recipient pairs. The general strategy was to initiate MUD search as soon as the indication for transplantation was established. Haploidentical transplantation was performed in patients with an initially unfavorable search result or failure to identify a matched donor within 3 months. Patients with refractory disease received a haploidentical transplantation upfront. Refractory disease was defined as 420% blasts in bone marrow after standard two courses of induction therapy (cytarabine/daunorubicine/ etoposide and high-dose cytarabine/mitoxantrone) and one course of fludarabine/cytarabine/mitoxantrone chemotherapy. Median time from formal transplant indication to transplantation was 191 day for MUD and 161 day for haplo, P = n.s. Disease status at transplant was CR #1 in 22 patients, CR ⩾ 2 in 5 patients and active disease (AD) in 6 patients. Among those transplanted in AD, four patients with chemorefractory disease were transplanted from haploidentical donors and two patients with early untreated relapse-from MUDs. Transplantation in CR1 was performed according to the risk stratification scheme in the current institutional AML protocol. Initial patient characteristics are presented in Table 1 . The preparative regimen (total dose, infusion days) included the following: treosulfan at 14 g/m 2 per day, day − 5, − 4, − 3; melphalan at 140 mg/m 2 per day, day − 2; fludarabine at 30 mg/m 2 per day, day − 6, − 5, − 4, − 3, − 2; and horse anti-thymocyte globulin (ATGAM, Pfizer ) at 25 mg/kg per day, day − 8, − 9 (14 patients) or day − 5, − 4 (19 patients).
Hematopoietic stem cell grafts were derived from a peripheral blood mononuclear cell fraction that was obtained using large-volume apheresis after a standard granulocyte colony-stimulating factor (G-CSF) mobilization regimen. TCR-alpha/beta and CD19 depletion was performed with a CliniMACS Plus instrument (Miltenyi Biotec, Bergish Gladbach, Germany) according to the manufacturer's recommendations. Graft composition was analyzed according to the manufacturer's protocol. The median log depletion was 4.2 (3.0-5.3) for αβ-T cells and 3.2 (2.0-3.9) for CD19+ cells. The comparative characteristics of the unrelated and haploidentical donors and grafts are presented in Table 2 . Post-transplant GvHD prophylaxis was tailored to the dose of TCR-alpha/ beta cells in the graft and donor type in 18 patients and uniform in 15 patients. Twenty-one patients received tacrolimus at 0.02 mcg/kg per day until day +30 and short methotrexate at 10 mg/m 2 on day +1, +3, +6. Mtx monotherapy was used in five patients, single agent tacrolimus in two patients and no prophylaxis in five patients. Supportive care included nursing in HEPA-filtered rooms, fluconazole as basic antifungal prophylaxis and did not include routine G-CSF use. Viral infections were subject to preemptive therapy. CMV, EBV and adenovirus were monitored weekly in the blood using quantitative PCR. Gancyclovir therapy was initiated after any positive CMV PCR and continued until two negative results. Rituximab was used in cases of EBV DNA load 410 000 genome equivalents/ml on two consecutive weeks or evidence of concomitant lymphoproliferation.
Engraftment of neutrophils was registered on day 1 of 3 consecutive days of ANC40.5 × 10 9 /L, and engraftment of platelets was registered on day 1 of three consecutive days of platelet count 420.0 × 10 9 /L unsupported by transfusion. Acute GvHD (aGvHD) and chronic GvHD (cGvHD) were diagnosed and graded according to standard guidelines. 16 Lymphohematopoietic chimerism in unfractionated bone marrow, CD34 and CD3 fractions was analyzed monthly until day +180 using the in house reverse transcriptase-PCR system for the detection of STR markers, then once every 3 months until day +360. For patients with 410% increase in mixed chimerism in the CD34+ fraction or bone marrow therapeutic donor lymphocyte infusions (DLIs) were allowed at the discretion of the attending physician. The initial unselected DLI dose was 25 × 10 3 /kg in haploidentical transplants and 5 × 10 5 /kg in unrelated grafts. Four patients received therapeutic DLI at a median of day +180. Patients who were at high-risk of leukemia relapse were eligible for a trial of preventive modified DLIs consisting of parts of the original graft depleted of αβ-T and CD19 lymphocytes. Thirteen patients received a median of three modified preventive DLIs. Median time to prophylactic DLI was 46 (40-105) days. All DLIs were performed after cessation of the immune suppression. Immune reconstitution was monitored monthly using flow cytometric detection of major lymphocyte subpopulations in peripheral blood.
The study was approved by the local ethics committee of the Dmitriy Rogachev federal research center for pediatric hematology, oncology and immunology, in accordance with the Helsinki declaration, and patients and/or their legal guardians provided informed consent to participate in the study.
Statistical analysis
Primary end point was cumulative incidence of TRM at 1 year. Secondary end points included cumulative incidence of aGvHD and cGvHD, event-free survival (EFS), relapse-free survival (RFS) and OS. For EFS, death from any cause and relapse were considered events of interest, for RFS leukemia relapse was considered as an event of interest. Sample size of n = 30 was determined for a pilot trial, based on the expected rate of the primary end point event and feasible number of transplants during the study period. Thirty-three consecutive patients were eligible for the study and all were included into the final analysis. Distributions of numeric data were compared between the groups with Mann-Whitney U-test, proportions were compared with Fisher's exact test. TRM and relapse were considered to be reciprocal competing risks and were calculated according to the competing risk model. EFS, RFS and OS were calculated according to Kaplan-Meier. XLSTAT, Addinsoft, 2015 software was used for the statistical analysis. The analysis was performed on 05.12.2014 with a median follow-up of 1.76 years in the survivors. 
RESULTS

Engraftment and GvHD
Primary engraftment of neutrophils and platelets was achieved in 33 (100%) patients at a median of 16 and 14 days, respectively. No case of graft rejection occurred, and day +100 mortality was 0%. Acute grade II-III GvHD was diagnosed in 14 patients at a median of 33 days, the cumulative incidence of grade II-III aGvHD is 39% (95% CI: 26-60). No patient developed grade IV GvHD. The cumulative incidence of grade II aGvHD was 23% (95% CI: 17-49) (six of seven patients with grade II aGvHD only had skin involvement). The cumulative incidence of grade III aGvHD (all patients with skin+gastrointestinal involvement) was 16% (95% CI: 7-37). Of note, recipients of haploidentical grafts more commonly developed isolated skin GvHD, with a cumulative incidence of 40% (95% CI: 21-81) for haplo and 6% (95% CI: 1-39) for MUD, P = n.s.; gastrointestinal involvement was more common in MUD transplants with a cumulative incidence of 25% (95% CI: 12-54) for MUD and 8% (95% CI: 1-50) for haplo, P = n.s. In two patients, norovirus was detected in the stool when gastrointestinal GvHD was diagnosed, which further complicated the diagnosis. Signs of cGvHD developed in 10 patients at a median of 124 days. In seven patients, cGvHD developed after DLIs: in three patients after the planned modified DLI and in four patients after DLI prompted by increasing mixed chimerism. cGvHD was extensive in four patients and was limited in six patients. Cumulative incidence of cGvHD at 2 years is 30% (95% CI: 18-50). Among 23 surviving patients, 5 required continued immune suppression to control cGvHD at the last follow-up.
Viral infections
Cumulative incidence of CMV and EBV reactivation was 52% and 50%, respectively. CMV disease developed in two patients and contributed to death in both. Both patients received prolonged multi-agent immune suppression to control GvHD. The small sample size limited the power of the risk factor analysis, but systemic corticosteroid therapy for aGvHD seemed to be associated with an increased risk of CMV reactivation, with a cumulative incidence of 73% (95% CI: 54-99) vs 33% (95% CI: 17-64), P = n.s., which was confirmed in a larger patient cohort from our center with statistical significance. 17 Rituximab was used in two cases for high EBV-load and suspected EBV-disease.
Immune reconstitution
Immune reconstitution was rapid with median (range) CD3, CD8 and CD4 counts of 245 (0-1670), 135 (0-1170) and 40 (0-620) on day +30 and 720 (50-2980), 330 (10-1880) and 210 (10-840) on day +180, respectively. The natural killer cell compartment recovered rapidly, with a median natural killer cell count of 385 (0-2560) on day +30, and remained stable over the first year post transplant. The recovery of major lymphocyte subsets in the peripheral blood is shown in Figure 1 . Of note, the recovery of the naive T-cell compartment was not observed before day +150.
TRM, leukemia relapse and survival Three patients died of causes unrelated to leukemia relapse on days +220, +265 and +357 post transplant. All three patients received prolonged immune suppression, including corticosteroids to control GvHD in two patients and to control serositis of unknown etiology in one. The direct causes of death included viral infections in two patients (late CMV disease in one patient and adenovirus and CMV in one patient) and catheter-associated bacterial sepsis in one patient with extensive cGvHD.
Leukemia relapse developed in 10 patients at a median of 6.1 (1-14) months. Among the relapsed patients, six received further therapy and five underwent re-transplantation. Two of the relapsed patients remain in CR for 6 and 22 months after the second transplantation. The cumulative incidence of relapse and TRM at 2 years is 31% (95% CI: 18-51) and 10% (95% CI: 4-26), respectively, in the entire cohort. EFS, RFS and OS at 2 years were 60% (95%: 43-76), 68% (95%: 51-84) and 67% (95%: 50-84), respectively for the entire cohort as shown in Figure 2 .
Within subgroups, the cumulative incidence of relapse was 25% (95% CI: 11-53) in MUD and 40% (95% CI: 20-80) in haplo, whereas TRM was 17% (95%: 7-41) and 0%, respectively. At 2 years, EFS, RFS and OS in subgroups was as follows: EFS MUD 60% (95% CI: 38-81) and haplo 59% (95% CI: 31-87), RFS MUD 75% (95% CI: 56-94) and haplo 59% (95% CI: 31-87), OS MUD 65% (95% CI: 44-85) and haplo 73% (95% CI: 45-100).
The only factor that showed either a trend or significant correlation with the outcomes of interest was disease status at transplant. For patients transplanted in any CR vs AD, the 2-year EFS, RFS and OS were as follows: EFS CR 66% (95% CI: 48-84) vs EFS AD 33% (95% CI: 0-71), log-rank P = 0.059; RFS CR 77% (95% CI: 60-93) vs RFS AD 33% (95% CI: 0-71), log-rank P = 0.012; and OS CR 72% (95% CI: 53-90) vs OS AD 50% (95% CI: 10-90), log-rank P = 0.09. These results are shown in Figure 3 When analyzed within the CR group, 2-year EFS, RFS and OS for MUD and haplo transplants were as follows: EFS MUD 61% (95% CI: 38-83) and EFS haplo 78% (95% CI: 50-100); RFS MUD 78% (95% CI: 59-97) and RFS haplo 78% (95% CI: 50-100); OS MUD 67% (95% CI: 45-88) OS haplo 83% (95% CI: 53-100). These results are shown in Figure 4 . DISCUSSION Historically, graft rejection and GvHD have been the major barriers to success in haploidentical transplantation. Profound T-cell depletion using CD34-selection and the use of 'mega' doses of highly purified hematopoietic stem cells were shown to overcome these obstacles, but consecutive prolonged immune deficiency was linked to a high incidence of severe infections and TRM. 10, 18 Selective depletion of TCR-alpha/beta-and CD19-positive lymphocytes was proposed as a method to further improve the results of transplantation from haploidentical donors. 11, 13 We used this method to process grafts from both unrelated and haploidentical donors in a pilot trial in order to improve the previously observed high, up to 30%, TRM rate at our institution after MUD transplantation. Within the current study we were able to achieve a high rate of primary engraftment in both unrelated and haploidentical grafts, despite the fact that 50% of the patients received o 10 × 106/kg of CD34+ cells, which suggests that the 'mega dose' requirement might not be relevant for this type of graft processing. The incidence of severe forms of aGvHD was relatively low, confirming the effectiveness of the method. It should be noted that the abbreviated course of conventional post-transplant GvHD prophylaxis surprisingly was not able to control aGVHD. The greater incidence of aGvHD than suggested by the Rome and Tuebingen groups may in part be related to the details of pretransplant serotherapy. 14 In particular, horse antithymocyte globulin, which was used in our trial, is less immunosuppressive than rabbit anti-thymocyte globulin, which was used in other trials. 19 Another detail that potentially contributed to the better GvHD control in the reports from the Rome group is that rituximab was included in the preparative regimen.
14 The true incidence of cGvHD is masked by the liberal use of DLIs and cannot be interpreted with certainty. To summarize, we believe that the addition of conventional post-transplant prophylaxis is not beneficial and that alternative maneuvers should be tested to further improve the control of GvHD.
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The pattern of immune reconstitution resembles the results reported, although we do not detect the universal early surge of gamma/delta T cells, which could be related to post-transplant pharmacological immune suppression with tacrolimus in our cohort. 14, 15 It should be noted that subpopulations of naive CD8 and CD4 T cells did not appear in peripheral blood before day +150. This finding suggests that good quantitative recovery of the T-cell population at earlier time points is most likely the result of oligoclonal expansion of the limited number of T cells from the graft, as suggested by other studies of immune recovery after T-cell depletion. 20, 21 This partly explains the fact that although the overall quantitative immune reconstitution was rapid, viral infections remained a serious problem and contributed significantly to the TRM in our patients. Control of these infections was further complicated by the limited access to adoptive cell therapy for viral infections. Acute toxicity of the procedure was low with zero 100-day TRM and generally early discharge to outpatient services. The use of a treosulfan-based preparative regimen and the CR1 status in most patients could also contribute to the low early mortality. 22 We suggest that further TRM decreases can be expected with improvements in GvHD control and the prophylactic use of adoptive immunotherapy of viral infections. Leukemia relapse remained the major cause of treatment failure. Extensive risk factor analysis was not possible due to limited sample size, but the influence of disease status at transplant was clear. We believe that the relapse rate of 22% for patients transplanted in remission is a promising result for high-risk AML, whereas patients with AD will require complimentary approaches to change the grim prognosis.
Comparison of haploidentical and unrelated transplantation was not the primary goal of the pilot trial, but our data suggest that the engraftment rate, GvHD rate and viral reactivation rate did not differ between these groups. Although a formal non-inferiority trial of haploidentical vs MUD transplantation in pediatric leukemia will be difficult to organize, our results support the conclusions of larger studies and current trends in donor selection. 6, 23 We conclude that the use of TCR-alpha/beta and CD19 depletion for ex vivo processing of haploidentical and unrelated grafts ensures a high engraftment rate, low incidence of aGvHD and TRM and enhanced immune reconstitution in children with AML. Taking into account the frequency of DLI use, the relative impact of different components of the transplantation procedure on cGvHD and relapse incidence could not be evaluated with confidence. The overall value of this type of graft manipulation for pediatric AML can be further improved with the use of novel approaches to post-transplant cellular therapy for leukemia and viral infections. 24 We also believe that the role of allo hematopoietic stem cell transplantation in CR1 in intermediate and high-risk pediatric AML should be periodically re-evaluated, given that the increasing safety of MUD and haploidentical donor transplantation and the almost 100% availability of the transplant procedure may improve the chance of cure with first line of therapy. 
